Galactosemic neuropathy in transgenic mice for human aldose reductase

Diabetes

Volumn 45, Issue 1, 1996, Pages 56-59

  Yagihashi, Soroku ^a   Yamagishi, Shin Ichiro ^a   Wada, Ryuichi ^a   Sugimoto, Kazuhiro ^a   Baba, Masayuki ^a   Wong, Hong Gang ^b   Fujimoto, Junichiro ^b   Nishimura, Chihiro ^b   Kokai, Yasuo ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; GALACTITOL; GALACTOSE; POLYOL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; GALACTOSEMIA; GENE EXPRESSION; MOTOR NERVE CONDUCTION; MYELINATED NERVE; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; SURAL NERVE; TRANSGENIC MOUSE;

EID: 0030048872     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.1.56     Document Type: Article

References (40)

1. Gabbay KH: The polyol pathway and the complications of diabetes. N Engl J Med 288:831-836, 1973
2. Clements RS Jr: Diabetic neuropathy new concepts of its etiology. Diabetes 28:604-611, 1979
3. Kinoshita JH, Nishimura C: The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 4:323-337, 1988
4. Kador PF: The role of aldose reductase in the development of diabetic complications. Med Res Rev 8:325-352, 1988
5. Dvornik D: Aldose Reductase Inhibition. New York, McGraw Hill, 1986
6. Sato S, Kador PF: NADPH-dependent reductases of the dog lens. Exp Eye Res 50:629-634, 1990
7. +)-ATPase activity in galactose intoxication Metabolism 40: 1207-1212, 1991
8. Engerman RL, Kern TS: Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42:820-825, 1993
9. Frank RN: Aldose reductase controversy. Diabetes 43:169-172, 1994
10. Sima AAF, Bril V, Nathaniel V, McEwen TAJ, Brown MB, Lattimer SA, Greene DA: Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 319:548-555, 1988
11. Bhoyrul S, Sharma AK, Stribling D, Mirrlecs DJ, Peterson RG, Farber MO, Thomas PK: Ultrastructural observations on myelinated fibers in experimental diabetes: effect of the aldose reductase inhibitor ponalrestat given alone or in conjunction with insulin therapy. J Neurol Sci 85:131-147, 1988
12. Yagihashi S, Yamaoka T, Nishimura C, Yamagishi S, Sugimoto K, Kokai Y: Establishment of mice transgenic for human aldose reductase. characterization and effects of galactose feeding. Diabetes 41 (Suppl. 1):105A, 1993
13. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase. Diabetologia 38:255-261, 1995
14. Nishimura C, Matsuura Y, Kokai Y, Akera T, Carper DA, Lyons C, Flynn TG: Cloning and expression of human aldose reductase. J Biol Chem 265:9788-9792, 1990
15. Hogan B, Constantini F, Lacy E: Manipulating the Mouse Embryo: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1986
16. Nishimura C, Hamada Y, Tachikawa T, Ishikawa T, Gui T, Tsubouchi J, Hotta N, Tanimoto T, Urakami T: Enzyme immunoassay for erythrocyte aldose reductase. Clin Chem 40:889-894, 1994
17. Shi Z-R, Itzkowitz SH, Kim YS: A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Catochem 36:317-322, 1988
18. Stribling D, Mirrlees DJ, Harrison HE, Earl DCN: Properties of ICI 128,436, a novel aldose reductase inhibitor and its effects on diabetic complications in the rat. Metabolism 34 (Suppl.):336-344, 1985
19. Yagihashi S, Kamrjo M, Ido Y, Mirrlees DJ: Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Diabetes 39.690-696, 1990
20. Dyck PJ, Giannini C, Lais A: Pathologic alterations of nerves. In Peripheral Neuropathy. 3rd ed. Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, Eds. Philadelphia, W.B. Saunders Co., 1993, p. 514-595
21. Nishimura C, Furue M, Ito T, Omori Y, Tanimoto T: Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Biochem Pharmacol 46:21-28, 1993
22. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316:599-606, 1987
23. Sharma AK, Thomas PK, Baker RWR: Peripheral nerve abnormalities related to galactose administration in rats. J Neurol Neurosurg Psychiat 39:794-802, 1976
24. Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia 37:141-144, 1994
25. Nukada H, Dyck PJ, Low PA, Lais AC, Sparks MF: Axonal caliber and neurofilaments are proportionally decreased in galactose neuropathy. J Neuropath Exp Neurol 45:140-150, 1986
26. Powell HC, Myers RR: Schwann cell changes and demyelination in chronic galactose neuropathy. Muscle Nerve 6:218-227, 1983
27. Forcier NJ, Mizisin AP, Rimmer MA, Powell HC: Cellular pathology of the nerve microenvironment in galactose intoxication. J Neuropath Erp Neurol 50:235-255, 1991
28. Myers RR, Powell HC; Galactose neuropathy: impact of chronic, endoneurial edema on nerve blood flow. Ann Neurol 16:587-594, 1984
29. Llewlyn JG, Patel PK, Thomas PK, Stribling D: Sodium, potassium adenosine triphosphatase activity in peripheral nerve tissue of galactosemic rats, effects of aldose reductase inhibition Diabetologia 30:971-972, 1987
30. Yagihashi S, Yamagishi S, Wada R, Sugimoto K, Nishimura C, Kokai Y, Hohman TC: Effects of long-term galactosemia on the peripheral nerve in transgenic mice expressing human aldose reductase (Abstract). Diabetes 44 (Suppl. 1):12A, 1995
31. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AAF, Greene DA. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabelotogia 36:608-614, 1993
32. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859, 1994
33. Kuck JFR: Response of the mouse lens to high concentrations of glucose or galactose. Ophthalmol Res 1:166-174, 1970
34. Varma SD, Kinoshita JH: The absence of cataracts in mice with congenital hyperglycemia. Exp Eye Res 19:577-582, 1974
35. Gillon KRW, Hawthorne JN: Sorbitol, inositol and nerve conduction in diabetes. Life Sci 32:1943-1947, 1983
36. Whiteley SJ, Tomlinson DR: Motor nerve conduction velocity, and nerve polyols in mice with short-term genetic or streptozotocin-induced diabetes. Exp Neurol 89:314-321, 1985
37. Llewlyn JG, Thomas PK, Mirrlees DJ: Aldose reductase activity and inyo-inositol levels in sciatic nerve and dorsal root ganglia of the diabetic mutant mouse [C57/BL/Ks(db/db)]. Metabolism 40:1084-1087, 1991
38. Calcutt NA, Willars GB, Tomlinson DR: Statil-sensitive polyol formation in nerve of galactose-fed mice. Metabolism 37:450-453, 1988
39. +-ATPase activity in galactose-fed mice: implications for polyol pathway and diabetic neuropathy. Diabetes 39 663-666, 1990
40. Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T: Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system Biochim Biophys Acta 1078:171-178, 1991